Ono Pharmaceutical’s consolidated sales for the fiscal year ending March 2026 are \u00a5515.7 billion (up 5.9% YoY), with net income of \u00a569.9 billion (up 39.4% YoY), achieving revenue and profit growth. The forecast for 2027 predicts sales of \u00a5455.0 billion and net income of \u00a57.1 billion.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4528","jir_company_name":"Ono Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-08","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4528-20260508-01.pdf","jir_short_summary":"Ono Pharmaceutical's consolidated sales for the fiscal year ending March 2026 are \u00a5515.7 billion (up 5.9% YoY), with net income of \u00a569.9 billion (up 39.4% YoY), achieving revenue and profit growth. The forecast for 2027 predicts sales of \u00a5455.0 billion and net income of \u00a57.1 billion.","jir_summary":"### Performance Overview\nOno Pharmaceutical's consolidated results for the fiscal year ending March 2026 recorded significant growth, with sales of \u00a5515.7 billion (up 5.9% YoY), operating income of \u00a592.3 billion (+54.4%), and net income of \u00a569.9 billion (+39.4%). Despite intensified domestic competition and generic entrants, overall business was strong, driven by increased overseas operations and royalty income. Continued investment in R&D facilitated clinical progress of new drug candidates and strategic partnerships. The outlook for 2027 projects sales of \u00a5455.0 billion and net income of \u00a57.1 billion, with ongoing growth ambitions.\n\n### Future Outlook and Investor Impact\nWhile next year's forecast suggests sales will decline approximately 11.8% to \u00a5455.0 billion, the company will maintain investment in R&D and partnerships to accelerate approval for new drug candidates and expand globally. Dividend payments are planned at \u00a580 per share annually, balancing shareholder returns with future investments. The company's solid financial foundation and proactive R&D and collaborations support long-term growth. Investors should focus on Ono Pharmaceutical\u2019s innovative drug development and stable financial status.","jir_financial_highlights":"Sales Revenue: \u00a5515.7 billion (Up 5.9% YoY)\nNet Income Attributable to Parent Company Owners: \u00a569.9 billion (Up 39.4% YoY)\nEarnings per Share (Parent Company Owners): \u00a5148.49 (Up \u00a541.98 YoY)","jir_category":"","jir_hashtags":"#OnoPharmaceutical, #IRFinancialResults, #JapaneseStocks","jir_key_figures":"Sales Revenue: \u00a5515.7 billion (up 5.9% YoY)\nNet Income Attributable to Parent Company Owners: \u00a569.9 billion (up 39.4% YoY)\nEarnings per Share (Parent Company Owners): \u00a5148.49 (up \u00a541.98 YoY)","jir_meta_title":"\u3010Ono Pharmaceutical\u3011Full-Year Financial Results for 2026\uff5cSales: \u00a5515.7 billion (+5.9%)","jir_meta_description":"Ono Pharmaceutical's fiscal year ending March 2026 results show sales of \u00a5515.7 billion and net income of \u00a569.9 billion, with growth. Also includes earnings guidance and future business outlook.","jir_og_title":"\u3010Ono Pharmaceutical\u30112026 Financial Results\uff5cSales: \u00a5515.7 billion, Net Income: \u00a569.9 billion","jir_og_description":"Ono Pharmaceutical's 2026 financial results report sales of \u00a5515.7 billion and net income of \u00a569.9 billion. Detailed outlook and investment points included.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7530,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-45224","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n